Canada Markets closed

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.19500.0000 (0.00%)
At close: 12:40PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

    VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time. Rakovina invites individual and institutional investors as well as advisors and

  • GlobeNewswire

    Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update

    VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for the quarter ended September 30, 2022 and provided a corporate update. Corporate Update Rakovina Therapeutics has continued to communicate progress in the Company’s research and development programs through presentations at pee

  • GlobeNewswire

    Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma

    Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), today announced publication of a scientific article on the anti-cancer activity of the Company’s novel dual PARP-HDAC inhibitor in models of Ewing sarcoma. The manuscript entitled “A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma”, indicate a bene